Abstract P6-13-04: Metformin for the treatment of ductal carcinoma in situ (DCIS)

CONCLUSION: Metformin inhibits the growth of DCIS and its progression to invasive breast cancer. To our knowledge, this is the first reported evidence of metformin’s anti-tumor activity in DCIS. Our data support the exciting prospect of developing metformin clinically for the treatment of DCIS.
Citation Format: Atreyi Dasgupta, David G Edwards, Frances S Kittrell, Susan G Hilsenbeck, Daniel Medina, Sao Jiralerspong. Metformin for the treatment of ductal carcinoma in situ (DCIS) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-13-04.

Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Dasgupta, A., Edwards, D. G., Kittrell, F. S., Hilsenbeck, S. G., Medina, D., Jiralerspong, S. Tags: Poster Session Abstracts Source Type: research